Eli Lilly Expands Collaboration with Camurus to Include Amylin Agonists
Eli Lilly (LLY) has expanded its collaboration with Camurus (CAMRF), exercising an option in their licensing agreement to access FluidCrystal technology for developing long-acting cardiometabolic drugs. This move enhances Eli Lilly's capabilities in drug development and could lead to innovative treatments.
Tickers: $LLY
Topics: cardiometabolic drugs pharmaceuticals technology licensing